Literature DB >> 20375601

Measure and countermeasure: type I IFN (IFN-alpha/beta) antiviral response against West Nile virus.

Stephane Daffis1, Mehul S Suthar, Michael Gale, Michael S Diamond.   

Abstract

As a first line of defense after viral infection, host cells develop an intrinsic immune response to control virus dissemination and protect against serious infection. Recent experiments have shown a dominant role of the IFN-alpha/beta response in protection against lethal West Nile virus (WNV) by limiting the cellular and tissue tropism of infection. This review will focus on advances in identifying the host sensors that detect WNV and the adaptor molecules and signaling pathways that regulate the induction of IFN-alpha/beta defenses that limit WNV replication, spread and pathogenesis. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20375601      PMCID： PMC2920482          DOI： 10.1159/000226248

Source DB:  PubMed          Journal:  J Innate Immun        ISSN： 1662-811X            Impact factor:   7.349


  82 in total

Review 1.  Recognition of viruses by innate immunity.

Authors:  Osamu Takeuchi; Shizuo Akira
Journal:  Immunol Rev       Date:  2007-12       Impact factor: 12.988

Review 2.  RNA recognition via TLR7 and TLR8.

Authors:  Veit Hornung; Winfried Barchet; Martin Schlee; Gunther Hartmann
Journal:  Handb Exp Pharmacol       Date:  2008

3.  Differential effects of mutations in NS4B on West Nile virus replication and inhibition of interferon signaling.

Authors:  Jared D Evans; Christoph Seeger
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

Review 4.  Sensing of viral infection and activation of innate immunity by toll-like receptor 3.

Authors:  Elisabeth Vercammen; Jens Staal; Rudi Beyaert
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 5.  MDA5/RIG-I and virus recognition.

Authors:  Osamu Takeuchi; Shizuo Akira
Journal:  Curr Opin Immunol       Date:  2008-02-12       Impact factor: 7.486

6.  Cholesterol manipulation by West Nile virus perturbs the cellular immune response.

Authors:  Jason M Mackenzie; Alexander A Khromykh; Robert G Parton
Journal:  Cell Host Microbe       Date:  2007-10-11       Impact factor: 21.023

Review 7.  PKR in innate immunity, cancer, and viral oncolysis.

Authors:  Siddharth Balachandran; Glen N Barber
Journal:  Methods Mol Biol       Date:  2007

8.  Differential activation of human monocyte-derived and plasmacytoid dendritic cells by West Nile virus generated in different host cells.

Authors:  Maria Carlan Silva; Antonieta Guerrero-Plata; Felicia D Gilfoy; Roberto P Garofalo; Peter W Mason
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

9.  Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1.

Authors:  Brenda L Fredericksen; Brian C Keller; Jamie Fornek; Michael G Katze; Michael Gale
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

10.  West Nile virus envelope protein inhibits dsRNA-induced innate immune responses.

Authors:  Alvaro Arjona; Michel Ledizet; Karen Anthony; Nathalie Bonafé; Yorgo Modis; Terrence Town; Erol Fikrig
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422
View more
  22 in total

Review 1.  Cell-intrinsic innate immune control of West Nile virus infection.

Authors:  Michael S Diamond; Michael Gale
Journal:  Trends Immunol       Date:  2012-06-20       Impact factor: 16.687

2.  Inhibitor of κB kinase epsilon (IKK(epsilon)), STAT1, and IFIT2 proteins define novel innate immune effector pathway against West Nile virus infection.

Authors:  Olivia Perwitasari; Hyelim Cho; Michael S Diamond; Michael Gale
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

Review 3.  Innate host responses to West Nile virus: Implications for central nervous system immunopathology.

Authors:  Giada Rossini; Maria Paola Landini; Francesco Gelsomino; Vittorio Sambri; Stefania Varani
Journal:  World J Virol       Date:  2013-05-12

4.  West Nile virus noncoding subgenomic RNA contributes to viral evasion of the type I interferon-mediated antiviral response.

Authors:  Andrea Schuessler; Anneke Funk; Helen M Lazear; Daphne A Cooper; Shessy Torres; Stephane Daffis; Babal Kant Jha; Yutaro Kumagai; Osamu Takeuchi; Paul Hertzog; Robert Silverman; Shizuo Akira; David J Barton; Michael S Diamond; Alexander A Khromykh
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 5.  Innate immune control of West Nile virus infection.

Authors:  Alvaro Arjona; Penghua Wang; Ruth R Montgomery; Erol Fikrig
Journal:  Cell Microbiol       Date:  2011-09-22       Impact factor: 3.715

Review 6.  West Nile virus population genetics and evolution.

Authors:  Kendra N Pesko; Gregory D Ebel
Journal:  Infect Genet Evol       Date:  2011-12-27       Impact factor: 3.342

7.  Increased early RNA replication by chimeric West Nile virus W956IC leads to IPS-1-mediated activation of NF-κB and insufficient virus-mediated counteraction of the resulting canonical type I interferon signaling.

Authors:  S V Scherbik; J A Pulit-Penaloza; M Basu; S C Courtney; M A Brinton
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

8.  Death receptor-mediated apoptotic signaling is activated in the brain following infection with West Nile virus in the absence of a peripheral immune response.

Authors:  Penny Clarke; J Smith Leser; Eamon D Quick; Kalen R Dionne; J David Beckham; Kenneth L Tyler
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

9.  Age-dependent myeloid dendritic cell responses mediate resistance to la crosse virus-induced neurological disease.

Authors:  Katherine G Taylor; Tyson A Woods; Clayton W Winkler; Aaron B Carmody; Karin E Peterson
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

10.  Cell-type-specific activation of the oligoadenylate synthetase-RNase L pathway by a murine coronavirus.

Authors:  Ling Zhao; L Dillon Birdwell; Ashley Wu; Ruth Elliott; Kristine M Rose; Judith M Phillips; Yize Li; Judith Grinspan; Robert H Silverman; Susan R Weiss
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.